Wells Fargo & Company MN Sells 50,854 Shares of Anika Therapeutics Inc (NASDAQ:ANIK)

Wells Fargo & Company MN lessened its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 17.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 238,066 shares of the biotechnology company’s stock after selling 50,854 shares during the quarter. Wells Fargo & Company MN’s holdings in Anika Therapeutics were worth $6,882,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Boston Trust Walden Corp raised its position in shares of Anika Therapeutics by 76.4% in the first quarter. Boston Trust Walden Corp now owns 387,747 shares of the biotechnology company’s stock valued at $11,210,000 after purchasing an additional 167,929 shares during the period. Goldman Sachs Group Inc. raised its holdings in Anika Therapeutics by 81.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 309,876 shares of the biotechnology company’s stock valued at $16,067,000 after acquiring an additional 138,695 shares during the period. State Street Corp lifted its position in shares of Anika Therapeutics by 14.7% during the fourth quarter. State Street Corp now owns 860,507 shares of the biotechnology company’s stock worth $44,617,000 after acquiring an additional 110,062 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Anika Therapeutics by 21.2% in the fourth quarter. Renaissance Technologies LLC now owns 585,129 shares of the biotechnology company’s stock worth $30,339,000 after acquiring an additional 102,207 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Anika Therapeutics by 1,197.5% during the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 97,276 shares of the biotechnology company’s stock valued at $2,812,000 after purchasing an additional 89,779 shares during the period. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Several equities research analysts have recently weighed in on ANIK shares. ValuEngine upgraded Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 4th. BidaskClub raised shares of Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, April 22nd. Zacks Investment Research downgraded shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, June 22nd. Finally, Barrington Research lowered shares of Anika Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $50.40.

Shares of Anika Therapeutics stock opened at $37.73 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.15 and a quick ratio of 4.81. Anika Therapeutics Inc has a 1 year low of $22.01 and a 1 year high of $75.71. The firm has a market cap of $493.95 million, a PE ratio of 15.89, a PEG ratio of 6.44 and a beta of 1.16. The company has a 50 day simple moving average of $33.59 and a two-hundred day simple moving average of $38.51.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.40 by ($0.16). The firm had revenue of $35.40 million for the quarter, compared to the consensus estimate of $36.06 million. Anika Therapeutics had a return on equity of 11.27% and a net margin of 20.87%. As a group, research analysts anticipate that Anika Therapeutics Inc will post 0.54 earnings per share for the current year.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Featured Story: What does a bar chart display?

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.